259 related articles for article (PubMed ID: 30703077)
1. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
[TBL] [Abstract][Full Text] [Related]
2. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
5. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152
[TBL] [Abstract][Full Text] [Related]
6. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
8. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
9. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
10. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
12. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Maréchal C; Lal H; Poder A; Ferguson M; Enweonye I; Heineman TC; Hervé C; Rheault P; Talli J; Wauters D; Oostvogels L
Vaccine; 2018 Jul; 36(29):4278-4286. PubMed ID: 29903674
[TBL] [Abstract][Full Text] [Related]
15. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).
Popmihajlov Z; Pang L; Brown E; Joshi A; Su SC; Kaplan SS; Willis ED
Hum Vaccin Immunother; 2018; 14(12):2916-2920. PubMed ID: 30024827
[TBL] [Abstract][Full Text] [Related]
16. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data.
Nelson JC; Ulloa-Pérez E; Yu O; Cook AJ; Jackson ML; Belongia EA; Daley MF; Harpaz R; Kharbanda EO; Klein NP; Naleway AL; Tseng HF; Weintraub ES; Duffy J; Yih WK; Jackson LA
Am J Epidemiol; 2023 Feb; 192(2):205-216. PubMed ID: 36193854
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology.
Tavares-Da-Silva F; Mahaux O; Van Holle L; Haguinet F; Seifert H; Stegmann JU
Drug Saf; 2020 Dec; 43(12):1223-1234. PubMed ID: 32862397
[TBL] [Abstract][Full Text] [Related]
18. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
[TBL] [Abstract][Full Text] [Related]
19. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]